Skip to main content
Premium Trial:

Request an Annual Quote

Ipsogen Licenses Xenomics' IP to Develop AML Dx

NEW YORK (GenomeWeb News) — Ipsogen today said it has co-exclusively licensed a biomarker from Xenomics linked to acute myeloid leukemia in order to develop and sell tests for the disease.  
  
Ipsogen’s diagnostics, which will be designed to stratify and monitor AML patients, will be based on NPM1 mutations that will integrate Ipsogen’s quantitative and standardized technology, including its FusionQuant and ProfileQuant tools, according to a statement.
 
"With this acute disease, physicians need a rapid assessment of patient prognosis for effective use of chemotherapy,” Xenomics CSO Samuil Umansky said in a statement.
 
He added that NPM1 “provides an excellent test for monitoring the minimal residual disease and patients in response to anti-tumor therapy.”
 
Financial terms of the agreement were not released.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.